ContraVir appoints new CMO
This article was originally published in Scrip
ContraVir Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, has named Dr John Sullivan-Bolyai chief medical officer. Most recently, Dr Sullivan-Bolyai was the executive director of infectious disease clinical research at Merck where he oversaw multiple HCV protocols in all three phases of clinical development. Prior to this, he was the vice-president of clinical research at Idenix.